CN116370622A - anti-PD-1 antibodies and their use in the preparation of a medicament for treating patients with urothelial cancer - Google Patents
anti-PD-1 antibodies and their use in the preparation of a medicament for treating patients with urothelial cancer Download PDFInfo
- Publication number
- CN116370622A CN116370622A CN202310584145.XA CN202310584145A CN116370622A CN 116370622 A CN116370622 A CN 116370622A CN 202310584145 A CN202310584145 A CN 202310584145A CN 116370622 A CN116370622 A CN 116370622A
- Authority
- CN
- China
- Prior art keywords
- antibody
- cells
- binding fragment
- antigen
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010044412 transitional cell carcinoma Diseases 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 2
- 230000027455 binding Effects 0.000 claims abstract description 31
- 239000012634 fragment Substances 0.000 claims abstract description 20
- 239000000427 antigen Substances 0.000 claims abstract description 19
- 102000036639 antigens Human genes 0.000 claims abstract description 19
- 108091007433 antigens Proteins 0.000 claims abstract description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 33
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 20
- 102000048362 human PDCD1 Human genes 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000001588 bifunctional effect Effects 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000004073 interleukin-2 production Effects 0.000 claims description 3
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 238000011824 transgenic rat model Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 description 50
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 25
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 25
- 210000004408 hybridoma Anatomy 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 210000004443 dendritic cell Anatomy 0.000 description 11
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 210000001616 monocyte Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 210000003289 regulatory T cell Anatomy 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- 230000000735 allogeneic effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 102000008096 B7-H1 Antigen Human genes 0.000 description 4
- 108091008048 CMVpp65 Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 229930189065 blasticidin Natural products 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000001114 myogenic effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 238000003345 scintillation counting Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 206010063836 Atrioventricular septal defect Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001211 electron capture detection Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000029584 urinary system neoplasm Diseases 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to the use of an anti-PD-1 antibody or antigen-binding fragment thereof in the treatment of urothelial cancer. Provides a new way for treating urothelial cancer.
Description
Technical Field
The invention belongs to the field of antibodies, and particularly relates to an anti-PD-1 antibody and application thereof in preparing a medicament for treating a patient with urothelial cancer.
Background
Urothelial cancer is a multi-source malignancy that originates from the urothelium, including renal pelvis cancer, ureter cancer, bladder cancer, and urinary tract cancer, the most common urinary system tumor. Among them, urothelial cancers can be classified into non-myogenic invasive urothelial cancers and myogenic invasive urothelial cancers.
The causes of urothelial cancer are relatively large, such as smoking, prolonged exposure to chemical poisons, drinking chlorinated or arsenic contaminated water, and frequent exposure to radiation. The treatment of urothelial cancer is generally consistent with other malignant tumors, and is comprehensively judged mainly according to the stage and severity of the disease and the physical condition of the patient. For patients with early surgical indications, the surgical treatment is carried out early, and if the patients are intolerant to the surgery or do not accord with the surgical indications, the comprehensive treatment such as radiotherapy, chemotherapy, targeted treatment and the like can be combined.
Although research and development of early diagnosis, surgical treatment and chemotherapy drugs for urothelial cancer have achieved a certain research result in recent years, mortality rate and recurrence rate of urothelial cancer within 5 years remain high, and on the other hand, the necessity of developing new drug treatment and treatment strategies has been demonstrated.
Disclosure of Invention
In order to overcome the problems in the background art, the invention provides an anti-PD-1 antibody and application thereof in preparing medicines for treating patients with urothelial cancer.
In order to achieve the above purpose, the invention is realized by the following technical scheme:
use of an anti-PD-1 antibody or antigen-binding fragment thereof in the manufacture of a medicament for treating a patient with urothelial cancer, wherein the antibody or antigen-binding fragment thereof comprises:
a heavy chain variable region comprising CDR1 shown in SEQ ID NO. 1, CDR2 shown in SEQ ID NO. 2 and CDR3 shown in SEQ ID NO. 3; and a light chain variable region comprising CDR1 shown in SEQ ID NO. 4, CDR2 shown in SEQ ID NO. 5 and CDR3 shown in SEQ ID NO. 6.
Further, the antibody or antigen binding fragment thereof is a fully human monoclonal antibody.
Further, the antibody or antigen binding fragment thereof, wherein the fully human monoclonal antibody is produced by a transgenic rat.
Further, the antibody or antigen binding fragment thereof, which blocks binding of human PD-1 to its ligand, and thus provides at least one of the following activities:
a) Induction of IL-2 production in cd4+ T cells;
b) Induction of ifnγ production in cd4+ T cells;
c) Inducing proliferation of cd4+ T cells; and
d) Reversing Treg inhibition function.
Further, the antibody or antigen binding fragment thereof is a bifunctional antibody (diabody), scFv dimer, dsFv, (dsFv) 2, dsFv-dsFv ', fv fragment, fab ', or F (ab ') 2.
Further, the antibody or antigen binding fragment thereof, the bifunctional antibody is BsFv or ds bifunctional antibody (ds diabody).
Further, the antibody or antigen binding fragment thereof further comprises an immunoglobulin constant region.
Further, the antibody or antigen binding fragment thereof further comprises a conjugate.
The invention has the beneficial effects that: the invention provides an anti-PD-1 antibody, and provides a new way for treating urothelial cancer.
Detailed Description
In order to make the objects, technical solutions and advantageous effects of the present invention more apparent, preferred embodiments of the present invention will be described in detail below to facilitate understanding by the skilled person.
Example 1: antibody hybridoma production
1.1 production of immunogens
Full length DNA encoding the ECDs of PD-1 and PD-L1 or both was synthesized and inserted into expression vector pcDNA3.3. Plasmid DNA was prepared in large quantities and the inserted DNA sequence was verified by sequencing. Fusion proteins of PD-1ECD and PD-L1ECD, prepared by transfection of the human PD-1ECD gene into CHO-S or HEK293 cells, contain a variety of tags, including human Fc, mouse Fc and His tags. After 5 days, the supernatant harvested from the transiently transfected cell culture was used for protein purification. The fusion proteins were purified and quantified for immunization and screening.
1.2 establishment of stable cell lines
To obtain tools for antibody screening and validation, PD-1 and PD-L1 transfected cell lines were established. Briefly, pCND3.3 expression vectors containing full length PD-1 or PD-L1 were transfected into CHO-K1, 293F or Ba/F3 cells using Lipofectamine 2000 transfection kit according to the manufacturer's instructions. 48-72 hours after transfection, the transfected cells are cultured in medium containing Blasticidin (Blasticidin) or G418 for selection. After a period of time, cells stably incorporating the PD-1 or PD-L1 gene in genomic DNA are selected. At the same time, it was verified whether the cells had the expression of the genes of interest PD-1 and PD-L1. Once the expression was verified, individual clones of interest were picked by limiting dilution and amplified to large capacity. The established monoclonal cell line is then maintained in medium containing the low dose antibiotic Blasticidin (Blasticidin) or G418.
1.3 establishment of antibody hybridomas
1.3.1 immunization and cell fusion: primary challenge immunization was performed on footpads using 8-1 0 week old OMT-rats (obtained from Open Monoclonal Technology, inc., palo Alto, US) with 10 μg of human PD-1ECD protein in TiterMax, and the immunization was repeated every 3 days with PD-1ECD formulated with aluminum. Rats were bled every 2 weeks and serum was collected and antibody titers were determined by ELISA or FACS tests. When the antibody titer reached high enough, the final adjuvant-free challenge (100 μl 1XPBS substitution) was given to the rats and cell fusion was performed as follows: b lymphocytes isolated from lymph nodes of immunized OMT-rats were cell fused with myeloma cells (at a 1:1 ratio). The cell mixture was washed and suspended with 5-10ml of ECF solution. The ECF solution was added to adjust the concentration to 2X10 6 Cells/ml. Immediately after cell electrofusion, the cell suspension in the fusion chamber was transferred into a sterile tube containing more volume of medium. After incubation at 37 ℃ for more than 24 hours, the cell suspension was mixed and pipetted into a 96-well plate (0.5x10) 6 Cell/plate). The cells were cultured at 37℃under 5% CO2. When the clones were large enough, 100 μl of supernatant was transferred from the 96-well plate for antibody screening test.
1.3.2 hybridoma supernatantsIs to be used for the first round and confirmation screening: ELISA assays were used as the first round of screening to test binding of hybridoma supernatants to PD-1 proteins. Briefly, plates were coated overnight at 4℃with 1. Mu.g/ml of soluble protein of the extracellular domain of human PD-1. After blocking and washing, the hybridoma supernatants were transferred to the coated plates and incubated for 1 hour at room temperature. The plates were then washed and then incubated with goat anti-rat IgG1HRP (Bethyl) and goat anti-rat IgG2b HRP (Bethyl) secondary antibodies for 45 minutes. After washing, TMB substrate was added and the reaction was quenched with 2M HCl. The absorbance at 450nm was read using a microplate reader (Molecular Device). To confirm the natural binding of PD-1 antibodies to conformational PD-1 molecules expressed on the cell membrane, FACS analysis was performed on PD-1 transfected CHO-S cell lines. At 1x10 6 Cell/ml concentration CHO-S cells expressing PD-1 were transferred to 96-well U-bottom plates (BD). The hybridoma supernatants were then transferred to the plates and incubated for 1 hour at 4 ℃. After washing with 1XPBS/1% BSA, goat anti-rat FITC (Jackson Immunoresearch Lab) secondary antibody was added and incubated with cells at 4℃for 1 hour in the dark. The cells were then washed and resuspended in 1XPBS/1% BSA or fixed in 4% formalin and analyzed by flow cytometry (BD). Binding of antibodies to maternal CHO-S cell lines was performed using the same method.
1.3.3 subcloning of hybridomas: once specific binding and blocking is verified by the first round and confirmation of screening, subcloning can be performed using the positive hybridoma cell line. Briefly, for each hybridoma cell line, cells were counted and diluted to 5 cells/well, 1 cell/well, and 0.5 cells/well in cloning medium. 200 μl/well was plated into 96-well plates, one plate at 5 cells/well, one plate at 1 cell/well and four plates at 0.5 cells/well. All plates were placed at 37℃with 5% CO2. Incubate until all cell lines can be checked by ELISA test.
Example 2: antibody hybridoma cell sequencing and fully human antibody characterization
2.1 antibody hybridoma cell sequencing: RNA was isolated from monoclonal hybridoma cells using Trizol reagent. VH and VL of PD-1 antibodies were amplified using the following protocol: briefly, first RNA was reverse transcribed into cDNA using reverse transcriptase as described herein, reaction system (20 μl):
mu.l of the PCR reaction product was taken and subjected to ligation with the pMD18-T vector. Top10 competent cells were transformed with 10. Mu.l ligation product and the mixture was transferred to 2-YT+cab plates pre-warmed according to standard protocols and incubated overnight. Positive clones were checked by PCR using M13-48 and M13-47 primers, followed by sequencing.
2.2 construction of fully human antibody molecules: VH and VL of PD-1 antibodies were amplified as described above. The PCR reaction products were purified by PCR clean-up kit and VL and pCI vectors were digested with restriction enzymes Pme I and BssH II at 37℃for 2 hours. The reaction products were electrophoresed in a 1% agarose gel and gel extracted according to manufacturer's instructions. The digested VL and pCI vectors were ligated using the following procedure:
the mixture was incubated at 16℃for 30 minutes. Transformation and clonal expansion were performed with 10. Mu.l of reaction product. Plasmid pCI-VL DNA was extracted using the confirmed clone. The pCI-VL vector and VH fragment were then digested with Xbal and Sal I and purified digested VH and vector were ligated using T4DNA ligase at 16℃for 30 min. Once the sequence of the inserted VL and VH was verified by sequencing, transient transfection and establishment of stable cell lines were performed using expression vectors containing whole IgG of fully human PD-1 antibodies.
Example 3: characterization of fully human antibodies
3.1 full kinetic binding affinity of Surface Plasmon Resonance (SPR) assay: the affinity and binding kinetics of antibodies to PD-1 were characterized by the SPR method using Proteon XPR36 (Bio-Rad). Protein A protein (Sigma) was immobilized on a GLM sensor chip (Bio-Rad) by amine coupling. Purified antibodies were flowed through the sensor chip and captured by protein a. The chip was rotated 90℃and washed with running buffer (1 XPBS/0.01% Tween20, bio-Rad) until baseline stabilized. 5 concentrations of human PD-1 and running buffer were flowed through the antibody flow cell at a flow rate of 100. Mu.L/min, followed by a combined phase flow of 240s and then a dissociated phase of 600s. The chips were regenerated after each run with H3PO4 at pH 1.7. Binding and dissociation curves were fitted to a 1:1 Langmiur binding model using ProteOn software.
3.2 binding affinity of PD-1 antibodies to cell surface PD-1 molecules as determined by flow cytometry (FACS): the binding affinity of the antibodies to cell surface PD-1 was tested by FACS analysis. At 5x10 5 Cell/ml concentration CHO-S cells expressing PD-1 were transferred to 96-well U-bottom plates (BD). The antibodies to be tested were serially diluted 1:2 (1 XPBS/1% BSA) with wash buffer and incubated for 1 hour at 4 ℃. Secondary anti-goat anti-human IgG Fc FITC (3.0 moles FITC per mole IgG, (Jackson Immunoresearch Lab)) was added and incubated at 4℃for 1 hour in the dark. Cells were then washed once and resuspended in 1XPBS/1% BSA and analyzed using flow cytometry (BD). Based on the quantified beads (QuantumTM MESF Kit (Bangs Laboratories, inc.)), the fluorescence intensity was converted into a bound molecule on each cell. KD was calculated using Graphpad Prism 5.
3.3 effects of human PD-1 antibodies on T cell proliferation. The effect of PD-1 antibodies on T lymphocyte proliferation was tested using an allogeneic response. Primary Dendritic Cells (DC) -stimulated MLR were performed in 200 μl RPMI 1640 containing 10% FCS and antibiotics in 96 well U-bottom tissue culture plates. DC was combined with 1X10 5 Allogeneic total CD4 of (C) + T cells were mixed in a ratio of 1:10 and 1:100 DC to T cells. Culturing in the presence or absence of neutralizing mAb: the human PD-1 antibody and reference antibodies A and B were used at a concentration of 10. Mu.g/ml. Incubation test for 5 days, 1 uCi/well added during the last 16 hours [ 3 H]Thymidine. Determination by scintillation counting [ 3 H]Thymidine incorporation, with three-well averaging [ 3 H]Thymidine incorporation (counts per minute) indicates a proliferative response. DC only counts were conventionally<1000cpm. The results shown are representative examples of a minimum of 5 trials performed.
Human Dendritic Cells (DC) and CD4 for use in the above allogeneic MLR + T、CD8 + T and total cells were generated from PBMCs as follows: human monocytes were purified from PBMCs by negative selection using human monocyte concentration kit (human monocyte enrichment cocktail kit) according to the instructions of the manufacturer (StemCell menu). Briefly, ficol is usedThe l-Paque gradient isolates PBMCs from healthy donor blood. Cells were washed twice with PBS, then 1X10 in separation buffer 8 Cells/ml were resuspended and the Ab mixture was incubated with monocyte concentration for 30 min at 4 ℃. Unlabeled monocytes passed through MACS column were collected. To generate iDC, monocytes are cultured with GM-CSF (PeproTech, rocky Hill, NJ; 800U/ml) and IL-4 (PeproTech; 500U/ml) at a cell concentration of 2X10 in a medium of RPMI 1640 containing 10% FCS and antibiotics 6 Cells/ml. Half of the medium was replaced daily with medium containing GM-CSF and IL-4. The iDC was stimulated with LPS (026:B6; sigma-Aldrich, st. Louis, MO; 1. Mu.g/ml) for an additional 24 hours on day 5 to generate mature DCs. By combining PBMC with human CD4 according to the manufacturer's instructions (Stemsep) + T、CD8 + Negative selection of T and Total T cell concentrate mixtures and magnetic colloid incubation for purification of CD4 + T、CD8 + T and total T cells.
Human CD4+ T cells were stimulated with allogeneic DCs in the presence or absence of PD-1 antibodies 1.7.3hAb, 1.49.9hAb, 1.103.11hAb, 1.139.15hAb, and 1.153.7 hAb. Warp [ warp ] 3 H]Assessment of thymidine incorporation CD4 + Proliferation of T cells. 1.7.3hAb, 1.49.9hAb, 1.103.11hAb, 1.139.15hAb and 1.153.7hAb increased concentration-dependent T cell proliferation.
3.4 effects of in vitro human PD-1 antibodies on cytokine IFNγ secretion: to evaluate the blocking effect of human PD-1 antibodies on the production of the cytokine IFNγ, we performed experiments on the production of IFNγ in allogeneic-MLR. Briefly, CD4 was used according to the manufacturer's instructions + T cell concentration kit (CD 4) + T cell enrichment cocktail kit) negative selection of human CD4 + T cells were purified from PBMCs. Immature DCs were generated in monocytes cultured for 5 days in GM-CSF and IL-4 and differentiated to mature DCs by overnight stimulation with LPS at 1 μg/ml. CD4 + T cells and iDC/mDC were mixed in a T:1 and 100:1 ratio of T to DC. The culture is performed in the presence or absence of the human PD-1 antibody and the reference antibody. After 5 days, the supernatant of each culture was collected and assayed for cytokine ifnγ. Ifnγ levels in the supernatant were determined by ELISA test. Briefly, use ofAnti-human IFNγ mAb diluted in coating buffer coated Maxisorp plates (0.75. Mu.g/ml; i.e., diluted 1/1360), 50. Mu.l/well (i.e., 3.7. Mu.l antibody was added to a full 96-well plate to 5ml coating buffer) and incubated overnight at 4 ℃. Blocking buffer 200 μl/well was added for 2 hours to block excess protein binding capacity. Recombinant IFNγ dilutions were prepared as standard solutions and double dilutions were made from 8000pg/ml to 125pg/ml with complete medium, plus the case with complete medium only. The plates were washed, added with standard solution and test supernatant (100. Mu.l/well), and incubated for 2-4 hours. Biotinylated anti-IFNγ mAb (1/1333) in blocking buffer was added followed by additional avidin peroxidase. The reaction was performed by adding TMB substrate and quenched with 2M HCl. Absorbance was measured at 450 nm.
The results show that human CD4 was stimulated with allogeneic DCs in the presence or absence of the 1.7.3hAb, 1.49.9hAb, 1.103.11hAb, 1.139.15hAb and 1.153.7hAb antibodies + T cells. Ifnγ levels were determined by ELISA. The results showed that fully human PD-1 antibodies increased ifnγ secretion in a dose dependent manner.
3.5 in vitro Effect of human PD-1 on Interleukin 2 (IL-2) production: CD4 + T cells and iDC/mDC were mixed in a T:1 and 100:1 ratio of T to DC. The culture is performed in the presence or absence of the human PD-1 antibody and the reference antibody. After 5 days, the supernatant from each culture was collected and assayed for cytokines. IL-2 levels in supernatants were determined by ELISA testing.
The results show stimulation of human CD4 with allogeneic DCs in the presence or absence of the antibodies of the present application or control antibodies + T cells. IL-2 levels were determined by ELISA. The results showed that fully human PD-1 antibodies increased ifnγ secretion in a dose dependent manner. The results show that anti-PD-1 antibodies increase IL-2 secretion in a dose dependent manner.
3.6 Effect of human PD-1 antibodies on cell proliferation and cytokine production by autoantigen-specific immune responses: in this assay, T cells and DC cells are from the same donor. Briefly, CD4 purification from PBMC + T cells were cultured in CMV pp65 peptide and low dose IL-2 (20U/ml),at the same time, DCs were generated from monocytes cultured in PBMC of the same donor in GM-CSF and IL-4. After 5 days, CD4 to be treated with CMV pp65 peptide was used + T cells were co-cultured with DCs pulsed with pp65 peptide in the presence or absence of human PD-1 antibody and reference antibody (as controls).
On day 5, 100. Mu.l of supernatant from each culture was used to determine the cytokines IFNγ and IL-2. Levels of ifnγ and IL-2 production were detected by ELISA assays. Specific T cell proliferation passage against pulsed addition of CMV pp65 peptide DC [ 3 H]And (3) measuring the incorporation of the thymidine.
The results show that PD-1 antibodies increased concentration-dependent CMV stimulated by autologous DCs loaded with CMV pp65 peptide + -CD4 + Proliferation of T cells.
3.7 Effect of human PD-1 antibodies on regulatory T-cell (Tregs) inhibition function: tregs are a subset of T cells that are critical immunomodulators, playing a critical role in maintaining self tolerance.
CD4 + CD25 + Regulatory T cells are associated with tumors because increased numbers of Tregs are found in various cancer patients and are associated with a poor prognosis. To directly assess the effect of human PD-1 antibodies on the immunosuppressive response, we performed Tregs experiments. CD4 was isolated using specific anti-CD 25 microbeads (Miltenyi Biotec, auburn, calif.) and positive or negative selection, respectively + CD25 + And CD4 + CD25 - T cells. Initially, human CD4 was used according to manufacturer's instructions (Stemsep) + The T cell concentrate mixture and magnetic colloid incubate PBMC, purifying cd4+ T cells via negative selection. Thereafter, CD4 was resuspended in MACS buffer + T cells, on ice and CD25 + The beads were incubated for 30 minutes, washed and loaded onto a column. CD4+CD25-T cells that did not bind to the column were collected from the effluent solution and washed prior to use. Subsequent recovery of CD4 from the column + CD25 + T cells were washed prior to use. Tregs are combined with CD4 in the presence or absence of a 10. Mu.g/ml concentration of a human PD-1 antibody + CD25 - T cells and DCs (Treg: teff ratio 1:1) were cultured. Without resistanceBody or isotype antibodies were used as negative controls. Supernatants from the cultures were taken on day 5 for ELISA to detect cytokines by addition at 1 uCi/well concentration [ 3 H]Thymidine and further incubation for 18 hours was used to detect cell proliferation. [ 3 H]Thymidine incorporation was by scintillation counting. The results showed that the PD-1 antibody removed Treg inhibitory function and restored responsive T cell proliferation and ifnγ secretion.
3.8ADCC/CDC assay: to make healthy PD-1 + Unwanted cytotoxicity was minimized and selected anti-PD-1 fully human antibodies were confirmed to be free of ADCC and CDC functions.
3.9ADCC: activated T cells expressing high levels of cell surface PD-1 were used as target cells and pre-incubated with different concentrations of fully human antibodies in 96-well plates for 30 min followed by addition of IL-2 activated PBMCs (used as Natural Killer (NK) cell sources, i.e. effector cells) at 50:1 effector/target cell ratio. The plates were incubated at 37℃in a 5% CO2 incubator for 6 hours. Target cell lysis was determined by cytotoxicity detection kit (Roche). The optical density was determined by a Molecular Devices SpectraMax M e microplate reader. The results show that the fully human anti-PD-1 antibodies tested did not mediate ADCC.
CDC: target cells (activated T cells), diluted human serum complement (Quidel-A112) and different concentrations of fully human PD-1 antibodies were mixed in 96-well plates. The plates were incubated for 4 hours at 37℃in a 5% CO2 incubator. Target cell lysis was determined by CellTiter glo (Promega-G7573). Rituxan (Roche) and human B lymphocyte fine Raji (CD 20 positive) served as positive controls. The data shows that the PD-1 antibodies do not mediate CDC.
Example 4: human body test research on efficacy and safety of anti-PD-1 antibody in treating refractory malignant tumors
The purpose is as follows: initial evaluation of anti-PD-1 antibodies for treatment of advanced refractory lymphomas and various solid tumors was performed with efficacy and safety.
The method comprises the following steps: the study inclusion criteria were age 18-75 years, ECOG 0-1, refractory solid tumors or lymphomas that did not receive PD-1/CTLA-4 treatment, as confirmed by the case study. The study included two phases, ia and Ib, with Ia being the up-dosing phase and Ib being the extended dosing phase. Patients enrolled in stage Ia received anti-PD-1 antibody treatment at a dose of 1, 4 or 10mg/kg once every 2 weeks (Q2W), or 240mg of Q3W or Q2W, respectively, with the primary purpose of assessing the Dose Limiting Toxicity (DLT) of the anti-PD-1 antibody to confirm RP2D. Stage ib 9 tumor patients received anti-PD-1 antibody RP2D single therapy and were evaluated for efficacy, once every 8 weeks (first 12 months) or 12 weeks (after 12 months), with evaluation criteria of RECIST 1.1 (solid tumor) or Lugano 2014 (lymphoma). Primary study endpoints were DLT (la) and efficacy (ib), secondary study endpoints included RP2D, maximum Tolerated Dose (MTD), and pharmacokinetics/pharmacodynamics (PK/PD), among others.
Results: by 18 months 4 of 2020, 289 patients (24 cases at Ia and 265 cases at Ib) were studied in the co-administration group. No DLT event occurred in stage Ia, determined RP2D to be 240mg Q2W; the tumor species incorporated in stage ib were gastric cancer (n=33), esophageal squamous carcinoma (n=33), hodgkin lymphoma (n=24), lung cancer (n=40), nasopharyngeal carcinoma (n=38), peripheral NK/T cell lymphoma (n=14), urothelial carcinoma (n=36), liver cancer (n=21), and cholangiocarcinoma (n=31), respectively. Patients were evaluated for efficacy in stage ib 260 and 62 patients for objective relief (complete relief or partial relief) with an overall Objective Relief Rate (ORR) of 23.8% and a median progression-free survival (PFS) of 2.86 months (95% ci: 1.4-3.2). The median total survival (OS) was 13.01 months (95% CI:10.38, 15.61) (Ia/Ib stage). The incidence of adverse events (TEAE) in any treatment during stage ib (265 cases) was 95.1%, and the incidence of TEAE grade 3 or above was 38.5%; the incidence of drug-related adverse reactions (TRAE) was 79.2%; the incidence of immune-related adverse reactions (irAE) was 33.6% (grade 3 or more, 4.9%). The efficacy of urothelial cancer is shown in Table 1 below.
TABLE 1 anti-PD-1 therapeutic efficacy for treating urothelial cancer
Conclusion: 240mg of anti-PD-1 antibody is used for intravenous drip (q 2 w) of urothelial cancer every 2 weeks, and has definite curative effect and good safety
Finally, it is noted that the above-mentioned preferred embodiments illustrate rather than limit the invention, and that, although the invention has been described in detail with reference to the above-mentioned preferred embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention as defined by the appended claims.
Claims (8)
1. Use of an anti-PD-1 antibody or antigen-binding fragment thereof in the manufacture of a medicament for treating a patient with urothelial cancer, wherein the antibody or antigen-binding fragment thereof comprises:
a heavy chain variable region comprising CDR1 shown in SEQ ID NO. 1, CDR2 shown in SEQ ID NO. 2 and CDR3 shown in SEQ ID NO. 3; and a light chain variable region comprising CDR1 shown in SEQ ID NO. 4, CDR2 shown in SEQ ID NO. 5 and CDR3 shown in SEQ ID NO. 6.
2. The use of claim 1, wherein the antibody or antigen-binding fragment thereof is a fully human monoclonal antibody.
3. The use of claim 1, the antibody or antigen binding fragment thereof, wherein the fully human monoclonal antibody is produced by a transgenic rat.
4. The use according to claim 1, said antibody or antigen binding fragment thereof, which blocks binding of human PD-1 to its ligand and thus provides at least one of the following activities:
a) Induction of IL-2 production in cd4+ T cells;
b) Induction of ifnγ production in cd4+ T cells;
c) Inducing proliferation of cd4+ T cells; and
d) Reversing Treg inhibition function.
5. The use of claim 1, wherein the antibody or antigen binding fragment thereof is a bifunctional antibody (diabody), scFv dimer, dsFv, (dsFv) 2, dsFv-dsFv ', fv fragment, fab ', or F (ab ') 2.
6. The use of claim 1, wherein the antibody or antigen binding fragment thereof, the bifunctional antibody is BsFv or ds bifunctional antibody (ds diabody).
7. The use of claim 1, wherein the antibody or antigen-binding fragment thereof further comprises an immunoglobulin constant region.
8. The use of claim 1, wherein the antibody or antigen-binding fragment thereof further comprises a conjugate.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211694699.7A CN115925954A (en) | 2022-12-28 | 2022-12-28 | anti-PD-1 antibody and application thereof in preparation of medicines for treating urothelial cancer patients |
CN2022116946997 | 2022-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116370622A true CN116370622A (en) | 2023-07-04 |
Family
ID=86557553
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211694699.7A Withdrawn CN115925954A (en) | 2022-12-28 | 2022-12-28 | anti-PD-1 antibody and application thereof in preparation of medicines for treating urothelial cancer patients |
CN202310584145.XA Pending CN116370622A (en) | 2022-12-28 | 2023-05-23 | anti-PD-1 antibodies and their use in the preparation of a medicament for treating patients with urothelial cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211694699.7A Withdrawn CN115925954A (en) | 2022-12-28 | 2022-12-28 | anti-PD-1 antibody and application thereof in preparation of medicines for treating urothelial cancer patients |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN115925954A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110072552A (en) * | 2016-10-14 | 2019-07-30 | 默沙东公司 | For treating PD-1 antagonist and the combination of Ai Libulin of bladder transitional cell carcinoma |
CN113893343A (en) * | 2021-10-16 | 2022-01-07 | 广州誉衡生物科技有限公司 | anti-PD-1 antibody and application thereof in preparation of medicine for treating cervical cancer patient |
CN116531503A (en) * | 2022-12-28 | 2023-08-04 | 广州誉衡生物科技有限公司 | anti-PD-1 antibodies and their use in the preparation of a medicament for treating gastric cancer patients |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210047408A1 (en) * | 2018-02-13 | 2021-02-18 | Merck Sharp & Dohme Corp. | Methods for treating cancer with anti-pd-1 antibodies |
KR102520974B1 (en) * | 2018-08-29 | 2023-04-17 | 레메젠 코, 리미티드 | Use of anti-HERH2 antibody-drug conjugate in the treatment of urothelial carcinoma |
-
2022
- 2022-12-28 CN CN202211694699.7A patent/CN115925954A/en not_active Withdrawn
-
2023
- 2023-05-23 CN CN202310584145.XA patent/CN116370622A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110072552A (en) * | 2016-10-14 | 2019-07-30 | 默沙东公司 | For treating PD-1 antagonist and the combination of Ai Libulin of bladder transitional cell carcinoma |
CN113893343A (en) * | 2021-10-16 | 2022-01-07 | 广州誉衡生物科技有限公司 | anti-PD-1 antibody and application thereof in preparation of medicine for treating cervical cancer patient |
CN116531503A (en) * | 2022-12-28 | 2023-08-04 | 广州誉衡生物科技有限公司 | anti-PD-1 antibodies and their use in the preparation of a medicament for treating gastric cancer patients |
Also Published As
Publication number | Publication date |
---|---|
CN115925954A (en) | 2023-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108124445B (en) | CTLA4 antibodies, pharmaceutical compositions thereof, and uses thereof | |
US20180044415A1 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
US10550196B2 (en) | Humanized antibodies against CEACAM1 | |
TW202320852A (en) | Anti-PD-1 antibody and application thereof to preparation of medicine for treating cervical cancer patients | |
CN112703012A (en) | Methods of treating cancer | |
CN116531503A (en) | anti-PD-1 antibodies and their use in the preparation of a medicament for treating gastric cancer patients | |
WO2022161425A1 (en) | Humanized antibody against tnfr2 and use thereof | |
CN115135344A (en) | Antibodies for use in therapy | |
KR20200014277A (en) | AMHRII-binding compounds for preventing or treating lung cancer | |
CN110546165A (en) | anti-PD-L1-anti-TIM-3 bispecific antibody | |
WO2021160267A1 (en) | Bispecific antibodies against cd9 and cd7 | |
CN113307874B (en) | anti-LAG3antibody and application thereof | |
WO2022121846A1 (en) | Pd-l1 antibody and application thereof | |
US20230312709A1 (en) | Antibody targeting CD47 and application thereof | |
CN116178545A (en) | Anti-human PD-L1 humanized antibody or antigen binding fragment thereof and application thereof | |
CN116370622A (en) | anti-PD-1 antibodies and their use in the preparation of a medicament for treating patients with urothelial cancer | |
CN114616245B (en) | anti-CD 38 antibody and application thereof | |
CN116585467A (en) | anti-PD-1 antibodies and their use in the preparation of a medicament for the treatment of esophageal squamous carcinoma patients | |
CN116549633A (en) | anti-PD-1 antibodies and their use in the preparation of a medicament for the treatment of patients with nasopharyngeal carcinoma | |
CN116474092A (en) | anti-PD-1 antibodies and their use in the preparation of a medicament for treating cholangiocarcinoma patients | |
CN110662764A (en) | Anti-programmed death ligand 1(PD-L1) antibodies and therapeutic uses thereof | |
CN116407629A (en) | anti-PD-1 antibody and application thereof in preparation of medicines for treating liver cancer patients | |
CN116077645A (en) | anti-PD-1 antibodies and their use in the preparation of a medicament for treating non-small cell lung cancer patients | |
CN114258402A (en) | anti-CD123 antibodies, anti-CD123 chimeric antigen receptors, and anti-CD123 chimeric antigen receptor T cells | |
CN117442718A (en) | anti-PD-1 antibodies and their use in the preparation of a medicament for the treatment of colon cancer patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |